Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy CandidatesPrograms receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidates

Acepodia完成4700万美元B系列融资,以推进同种异体细胞治疗候选项目的管道。接受资助的项目包括那些开发公司专有的冻存NK和伽马三角洲T细胞候选项目的项目

2021-03-17 05:30:14 BioSpace

本文共1477个字,阅读需4分钟

SAN MATEO, Calif., March 16, 2021 -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the closing of its $47 million Series B financing. The funding will be used to advance the company’s lead off-the-shelf natural killer cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic. Acepodia anticipates completing IND-enabling studies for two additional pipeline products in 2021. The funding round was supported by new U.S. institutional investors, including Ridgeback Capital Investments, 8VC, and DEFTA Partners, and the Taiwan-based institutional investor-CDIB Capital Healthcare. Acepodia’s Series A investors also participated. “This second capital raise for Acepodia represents a strong vote of confidence by our investors in our highly differentiated approach to cell therapy, particularly with NK cells, and in the Company’s potential to provide superior treatment options for patients with cancer,” said Sonny Hsiao, Ph.D., founder and chief executive officer of Acepodia. “Accessible and effective allogeneic, off-the-shelf cell therapies will be an important part of next generation cancer therapy. With our discipline and capital efficiency, we are well-positioned to execute on our corporate objectives, including the continued clinical development of these therapies, including our lead candidate, ACE1702 for the treatment of solid tumors, and execution of future clinical trial initiations for our promising preclinical portfolio of NK and NK-like gamma delta T cell therapy candidates.” Wayne Holman, M.D., Chief Executive Officer and Founder of Ridgeback Capital, added, “We are excited to participate in this financing for Acepodia as we are believers in the foundational evidence suggesting cell therapies should play a significant role in the future of cancer therapy. We believe the prior success of Acepodia’s leadership group in cell therapies, and the unique Antibody-Cell Conjugation (ACC) technology when applied to allogeneic off-the-shelf cryopreserved NK cells could lead to enhanced and differentiated results.” Acepodia’s technology enables development of cell therapies with improved tumor engagement and targeting through optimized cell receptor selection, and seamless conjugation with antibody therapies. Utilizing its proprietary, patent-protected Antibody-Cell Conjugation (ACC) technology, Acepodia is able to directly conjugate and arm NK or gamma delta T cells with validated anti-tumor antibodies for cell therapies, a design which has demonstrated the ability to overcome traditionally resilient tumor defenses in preclinical trials. The company is currently conducting an ongoing Phase 1 clinical trial of ACE1702, the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors. About Acepodia Acepodia is a privately held biotechnology company focused on eradicating cancers of all types with potent and targeted first-in-class cell therapies. The company’s next generation allogeneic natural killer (NK) cell therapies are based on a proprietary NK cell line (oNK) that has been selected for its potent anti-tumor activity. This cell line is further enhanced by the company’s proprietary ACC (Antibody-Cell Conjugation) technology that links tumor-targeting antibodies to the surface proteins of oNK cells to direct and maximize tumor cell killing. The company’s lead product candidate, ACE1702, is an antibody-conjugated NK cell therapy in clinical development at multiple U.S. cancer centers for the treatment of HER2-expressing solid tumors. For more information, visit https://www.acepodia.com. Acepodia Contact Spike Lo, Senior Director of Business Development Acepodia 886 (2) 2697-6100 spike@acepodiabio.com Investor Contact Sylvia Wheeler Wheelhouse Life Science Advisors swheeler@wheelhouselsa.com Media Contact Michael Tattory  LifeSci Communications 1 (646) 751-4362 mtattory@lifescicomms.com
加利福尼亚州圣马特奥,2021年3月16日--开发下一代实体肿瘤和血液癌细胞疗法的生物技术公司Acepodia今天宣布结束其4700万美元的B轮融资。这笔资金将用于通过实体肿瘤的临床开发来推进该公司领先的现成自然杀伤细胞治疗候选药物ACE1702,并将其临床前NK和伽马三角洲T细胞治疗管道推向临床。Acepodia预计在2021年完成另外两个管道产品的IND支持研究。 这轮融资得到了新的美国机构投资者的支持,包括Ridgeback Capital Investments、8VC和DEFTA Partners以及台湾机构投资者CDIB Capital Healthcare。ACEPODIA的A系列投资人也参与其中。 Acepodia公司创始人兼首席执行官Sonny Hsiao博士说:“Acepodia公司的第二次融资代表了我们的投资者对我们的高度分化的细胞治疗方法,特别是NK细胞的治疗方法,以及对公司为癌症患者提供优越治疗选择的潜力的强烈信心。易得和有效的同种异体,现成的细胞疗法将是下一代癌症治疗的重要组成部分。凭借我们的纪律和资本效率,我们完全有能力实现我们的公司目标,包括这些疗法的持续临床开发,包括我们的主要候选实体肿瘤治疗药物ACE1702,以及为我们有前途的NK和类NK伽马-三角洲T细胞疗法候选药物进行未来的临床试验。“ Ridgeback Capital公司的首席执行官兼创始人韦恩·霍尔曼医学博士补充说:“我们很高兴参与对Acepodia公司的这次融资,因为我们相信细胞疗法在未来癌症治疗中应该发挥重要作用的基础证据。我们相信,Acepodia领导小组在细胞治疗方面的先天成功,以及独特的抗体-细胞结合(ACC)技术应用于同种异体现成冷冻保存的NK细胞,可以导致增强和分化的结果。“ ACEPODIA的技术通过优化的细胞受体选择,以及与抗体治疗的无缝结合,使得能够开发具有改善肿瘤接合和靶向性的细胞疗法。利用其专利保护的抗体-细胞接合(ACC)技术,Acepodia能够直接将NK或gamma delta T细胞与经验证的抗肿瘤抗体接合和臂架,用于细胞治疗,这一设计在临床前试验中已证明有能力克服传统的弹性肿瘤防御。公司目前正在进行ACE1702的1期临床试验,ACE1702是临床开发中的第一种抗体结合NK细胞疗法,用于治疗表达HER2的实体瘤。 关于Acepodia Acepodia是一家私营生物技术公司,专注于用高效、靶向的一流细胞疗法根除所有类型的癌症。该公司的下一代异基因自然杀伤(NK)细胞疗法基于一种专有的NK细胞系(oNK),该细胞系因其强大的抗肿瘤活性而被选中。该公司专有的ACC(抗体-细胞结合)技术进一步增强了这种细胞系,该技术将肿瘤靶向抗体与oNK细胞的表面蛋白连接起来,以指导并最大限度地杀伤肿瘤细胞。该公司的主要候选产品ACE1702是一种抗体结合的NK细胞疗法,正在美国多个癌症中心进行临床开发,用于治疗表达HER2的实体肿瘤。欲了解更多信息,请访问https://www.acepodia.com。 Acepodia接触 高级业务发展总监罗伟辉 阿塞波迪亚 886(2)2697-6100 电子邮件:spike@acepodiabio.com 投资者联系人 西尔维娅·惠勒 Heolhouse生命科学顾问 @wheelhouselsa.com 媒体联系人 迈克尔·塔托里 LifeSci通信 1(646)751-4362 mtattory@lifescicomms.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文